Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Follow-Up Questions
Unicycive Therapeutics Inc 的 CEO 是谁？
Dr. Shalabh Gupta 是 Unicycive Therapeutics Inc 的 Chairman of the Board，自 2016 加入公司。
UNCY 股票的价格表现如何？
UNCY 的当前价格为 $4.09，在上个交易日 decreased 了 0%。
Unicycive Therapeutics Inc 的主要业务主题或行业是什么？
Unicycive Therapeutics Inc 属于 Biotechnology 行业，该板块是 Health Care
